

Dated: March 10, 2021.

**Lynette Wilson,**

*Federal Register Liaison, Department of Health and Human Services.*

[FR Doc. 2021-05322 Filed 3-12-21; 8:45 am]

BILLING CODE 4120-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy; Correction

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Department of Health and Human Services, National Institutes of Health published a Notice in the **Federal Register** on February 25, 2021. That Notice requires a correction in the **SUPPLEMENTARY INFORMATION** section.

#### SUPPLEMENTARY INFORMATION:

##### Correction

In the **Federal Register** of February 25, 2021, in FR Doc. 2021-03873, on page 11548, as found within the **SUPPLEMENTARY INFORMATION** section, correct to read:

The use of the Licensed Patent Rights to develop, manufacture, distribute, sell, and use autologous tumor infiltrating lymphocyte (TIL) adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers. Specifically excluded from this Agreement are cell therapy products involving TIL genetically modified for reactivity against cancer-specific mutations or TIL selected for reactivity against cancer-specific mutations, unless such cell therapy products are a combination of unselected, unmodified TIL therapy with the Licensee's proprietary technologies or the Licensee's in-licensed technologies.

The field of use described in the Notice was found to be incorrect. The correction addresses this discrepancy by accurately stating the field of use which the NIH intends to grant to Iovance Biotherapeutics, Inc for the disclosed federally owned invention.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)-276-5484; Email: [andy.burke@nih.gov](mailto:andy.burke@nih.gov).

Dated: March 9, 2021.

**Daniel R Hernandez,**

*Federal Register Officer, National Institutes of Health.*

[FR Doc. 2021-05272 Filed 3-12-21; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Development, Production, and Commercialization of Ebola Neutralizing Single Monoclonal Antibody for the Treatment of Ebola Virus Disease in Humans

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and European Patents and Patent Applications listed in the Supplementary Information section of this Notice to Ridgeback Biotherapeutics, L.P., located in Miami, Florida.

**DATES:** Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before March 30, 2021 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Daniel Lee, J.D., Technology Transfer and Patent Specialist, National Institute of Allergy and Infectious Diseases Technology Transfer and Intellectual Property Office by email ([daniel.lee5@nih.gov](mailto:daniel.lee5@nih.gov)) or phone (301-761-6327).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

*E-045-2015: Neutralizing Antibodies to Ebolavirus Glycoprotein and Their Use*

1. United States Provisional Patent Application No. 62/087,087, filed 3 December 2014 (HHS Reference No. E-045-2015-0-US-01);

2. International Patent Application No. PCT/US2015/060733, filed 13 November 2015 (HHS Reference No. E-045-2015-0-PCT-02);

3. European Patent Application No. 15797815.6, filed 13 November 2015 (HHS Reference No. E-045-2015-0-EP-03); and

4. United States Patent No. 10,273,288, issued 30 April 2019 (HHS Reference No. E-045-2015-0-US-05).

The patent and patent application rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the fields of use may be limited to the following: Development, production, and commercialization of Ebola neutralizing monoclonal antibody mAb114, as a single antibody not in combination with other monoclonal antibodies, for the treatment of Ebola virus disease in humans.

This technology discloses the discovery, isolation, production, and advancement in the development of recombinant neutralizing antibodies specific to the Ebola virus glycoprotein, varying Ebola virus glycoprotein recognition profiles, and increasing neutralization potency for a therapeutic in a patient diagnosed with Ebola virus.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Institute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent commercialization license. In response to this notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this notice will be presumed to contain business confidential information, and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 26, 2021.

**Surekha Vathyam,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2021-05235 Filed 3-12-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG-2021-0179]

#### Information Collection Request to Office of Management and Budget; OMB Control Number: 1625-0128

**AGENCY:** Coast Guard, DHS.

**ACTION:** Sixty-day notice requesting comments.

**SUMMARY:** In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an extension of its approval for the following collection of information: 1625-0128, Prospect Questionnaire, Chat Now Questionnaire, and the Officer Program Application; without change.

Our ICR describes the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below.

**DATES:** Comments must reach the Coast Guard on or before May 14, 2021.

**ADDRESSES:** You may submit comments identified by Coast Guard docket number [USCG-2021-0179] to the Coast Guard using the Federal eRulemaking Portal at <https://www.regulations.gov>. See the "Public participation and request for comments" portion of the **SUPPLEMENTARY INFORMATION** section for further instructions on submitting comments.

A copy of the ICR is available through the docket on the internet at <https://www.regulations.gov>. Additionally, copies are available from: Commandant (CG-6P), ATTN: Paperwork Reduction Act Manager, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE, STOP 7710, Washington, DC 20593-7710.

**FOR FURTHER INFORMATION CONTACT:** A.L. Craig, Office of Privacy Management, telephone 202-475-3528, or fax 202-372-8405, for questions on these documents.

**SUPPLEMENTARY INFORMATION:**

#### Public Participation and Request for Comments

This notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection's purpose, the Collection's likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection.

The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the Collection; (2) the accuracy of the estimated burden of the Collection; (3) ways to enhance the quality, utility, and clarity of information subject to the Collection; and (4) ways to minimize the burden of the Collection on respondents, including the use of automated collection techniques or other forms of information technology.

In response to your comments, we may revise this ICR or decide not to seek an extension of approval for the Collection. We will consider all comments and material received during the comment period.

We encourage you to respond to this request by submitting comments and related materials. Comments must contain the OMB Control Number of the ICR and the docket number of this request, [USCG-2021-0179], and must be received by May 14, 2021.

#### Submitting Comments

We encourage you to submit comments through the Federal eRulemaking Portal at <https://www.regulations.gov>. If your material cannot be submitted using <https://www.regulations.gov>, contact the person in the **FOR FURTHER INFORMATION CONTACT** section of this document for alternate instructions. Documents mentioned in this notice, and all public comments, are in our online docket at <https://www.regulations.gov> and can be viewed by following that website's instructions. Additionally, if you go to the online docket and sign up for email alerts, you will be notified when comments are posted.

We accept anonymous comments. All comments received will be posted without change to [https://](https://www.regulations.gov)

[www.regulations.gov](https://www.regulations.gov) and will include any personal information you have provided. For more about privacy and submissions in response to this document, see DHS's eRulemaking System of Records notice (85 FR 14226, March 11, 2020).

#### Information Collection Request

**Title:** Prospect Questionnaire, Chat Now Questionnaire, and the Officer Program Application.

**OMB Control Number:** 1625-0128.

**Summary:** This collection contains the recruiting website [gocoastguard.com](https://gocoastguard.com) Prospect Questionnaire (CGRC-1130), Chat Now Questionnaire (CGRC-1132), and the Officer Program Application (CGRC-1131) that are used to screen active duty, reserve, enlisted, and officer applicants.

**Need:** The information is needed to initiate the recruiting and commissioning of active duty, reserve, enlisted, and officer members. 14 U.S.C. 2701 authorizes the United States Coast Guard to recruit personnel for military service. The information requested on the [gocoastguard.com](https://gocoastguard.com) website is collected in accordance with Section 503 of Title 10 U.S.C. and may be used to identify and process individuals interested in applying for enlistment or commission into the United States Coast Guard or Coast Guard Reserve.

**Forms:** Online Application plus hard copy of the Prospect Questionnaire (CGRC-1130), and/or the Officer Program Application (CGRC-1131) if a prospect does not use [gocoastguard.com](https://gocoastguard.com), but contacts a recruiter directly.

**Respondents:** Approximately 50,000 applicants apply annually to initiate the screening process.

**Frequency:** Applicants may apply more than once, by initially completing the Chat Now Questionnaire (CGRC-1132) to answer questions on eligibility and may apply for both enlisted and officer programs through the Prospect Questionnaire (CGRC-1130) and/or Officer Program Application (CGRC-1131).

**Hour Burden Estimate:** The estimated burden remains 97,686 hours a year.

**Authority:** The Paperwork Reduction Act of 1995; 44 U.S.C. chapter 35, as amended.

Dated: March 9, 2021.

**Kathleen Claffie,**

*Chief, Office of Privacy Management, U.S. Coast Guard.*

[FR Doc. 2021-05265 Filed 3-12-21; 8:45 am]

**BILLING CODE 9110-04-P**